Signifier’s eXciteOSA Receives US FDA’s Approval for the Treatment of Mild Obstructive Sleep Apnea and Snoring

 Signifier’s eXciteOSA Receives US FDA’s Approval for the Treatment of Mild Obstructive Sleep Apnea and Snoring

Signifier’s eXciteOSA Receives US FDA’s Approval for the Treatment of Mild Obstructive Sleep Apnea and Snoring

Shots:

  • The FDA has approved eXciteOSA to treat mild obstructive sleep apnea and snoring by using for only 20 min./day for a period of 6 wks. and then twice per week
  • In a study of 65 mild obstructive sleep apnea patients, 79% responded to therapy with 52% mean reduction in AHI, 50% reduction in ODI, 3.9point reduction in ESS. In a pivotal study, eXciteOSA achieved nearly a 40% reduction in snoring time across 115 patients
  • eXciteOSA is the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring will be available in the US imminently

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post